Arch Biopartners Science

Learn about the company’s medical trials, clinical research and journal publications.

The Company

Learn why Arch is distinct – discover our approach and the team behind the science.

Investor Relations

Get stock information, press releases, financials and management’s discussion and analysis.

Advancing and building value

Explore Arch Biopartners public announcements, information, management’s analysis and the fundamentals behind the approach that makes Arch unique.
Arch works closely with the scientific community, universities and research institutions to advance and build the value of select preclinical technologies, develop the most promising intellectual property, and create value for its investors.
Arch has established a diverse portfolio that includes:
  • LSALT Peptide (Metablok), a potential treatment for inflammation, sepsis and cancer metastasis – in Phase II international clinical trials to treat patients hospitalized with COVID-19;
  • AB569, a potential new treatment for antibiotic resistant bacterial infections; and
  • ‘Borg’ peptide coatings that increase corrosion resistance and decrease biofilm on various medical grade metals and plastics.

Arch Biopartners’ Lead Drug LSALT Peptide to Enter the Canadian Treatments for COVID-19 (CATCO) Trial

  • LSALT Peptide (LSALT) is a novel drug candidate that targets acute organ inflammation in the lungs, liver and kidneys which is common in moderate to severe cases of COVID-19, regardless of variant type.
  • LSALT is the first novel therapeutic to join the Canadian Treatments for COVID-19 trial, a multi-centre adaptive, randomized, open-label, controlled clinical trial involving sixty-five hospitals across Canada.
  • CATCO is being conducted in conjunction with the World Health Organization’s SOLIDARITY trial, in collaboration with countries around the world and with support from ...
    Full Release

Unaware of Any Undisclosed Material Change

TORONTO, Oct. 15, 2021 (GLOBE NEWSWIRE) -- At the request of the Investment Industry Regulatory Organization of Canada (IIROC), Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) wishes to confirm that the Company’s management is unaware of any undisclosed material change in the Company’s operations that would account for the recent increase in market activity.

About Arch Biopartners

Arch Biopartners Inc. is a clinical stage company focused on the development of innovative technologies that have the potential ...
Full Release

Find out about the company’s recent advancements, new patents, corporate filings, information for investors and all progress updates on active clinical trials.
  • Browse all of the company’s material news releases.
  • Read the latest releases when they are published here or via email by subscribing to email alerts and news.
Arch Biopartners key stock indicators.
The Stock Performance page displays current and historical data for both of the Arch Biopartners symbols on the TSX Venture Exchange in Canada and the OTCQB Venture Exchange in the USA.
Please be sure to subscribe for email updates when the company issues news releases and to receive announcements of new scientific data and company events and presentations.
The company’s reports and filings include current filings as well as an archive for investors and the public for research and review:

View the complete Arch Biopartners Inc. filings archives at the SEDAR website here .

Investor Information
Stock data, insights, filings, latest news.

Subscribe for email updates

Get email alerts when news is published
Please check the options for Investor News and Science Updates to receive additional information about events and publications.

Please enable the javascript to submit this form

Science and research
Browse journal publications and information about ongoing developments

Latest Scientific Publications

Arch Biopartners science team’s published findings and articles in peer-reviewed journals.

Developing select technologies

Arch Biopartners scientists, key technologies, publications and ongoing studies and trials.
The company is led by experienced groups of scientists with an executive, board and advisors with scientific, pharmaceutical, biotechnology and corporate financial experience.
Science and Research Teams
  • LSALT Peptide (Metablok) is led by Dr. Stephen Robbins Ph. D., Dr. Donna Senger Ph. D. and Jennifer Rahn B Sc., M Sc. at the University of Calgary
  • AB569 and Respiratory Pseudomonas is led by Dr. Daniel J. Hassett Ph. D. at the University of Cincinnati, College of Medicine
  • BORG Peptide is led by Dr. Randall Irvin Ph. D., Dr. Dongyang Li Ph. D. and Dr. Elisabeth Davis Ph. D. at the University of Alberta
  • The Treatments for Inflammation team is led by Dr. Daniel Muruve Ph. D., Dr. Justin Macdonald Ph. D. and Dr. Paul Beck at the University of Calgary
Arch has established a diverse portfolio that includes:
  • LSALT Peptide (Metablok), a potential treatment for inflammation, sepsis and cancer metastasis – in Phase II international clinical trials to treat patients hospitalized with COVID-19;
  • AB569, a potential new treatment for antibiotic resistant bacterial infections; and,
  • ‘Borg peptide coatings that increase corrosion resistance and decrease biofilm on various medical grade metals and plastics.
The Arch Biopartners Science Teams have all participated and authored key papers and journal publications as a core part of their ongoing scientific research, discoveries and development.
  • Treatments for Inflammation publications surrounding the development of LSALT Peptide (Metablok) as a treatment for inflammation with broad application to prevent organ and tissue injury
  • AB569 publications describing AB569 as a novel bactericidal treatment for treatment resistant bacteria and Respiratory Pseudomonas
  • BORG Peptide publications discussing a peptide-based biological coating for enhanced corrosion resistance, strength and control of adhesion of bacteria and microbes.
  • Brain Tumor Stem Cell Targeting publications describe the development of a peptide-based delivery platform for targeting malignant brain tumors